Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, includ ...

Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as ...

A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...

Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.